PAR3 Inhibitors as Therapeutic for PainTechnology #ua16-176
Questions about this technology? Ask a Technology Manager
- Josef Vagner Associate Research Professor, BIO5 Institute
- Scott Boitano Professor, Physiology
- Theodore Price Associate Professor
- Gregory Dussor Assistant Professor, Pharmacology
- Managed By
- Rakhi Gibbons Asst. Director, Life Sciences (520) 626-6695
Title: PAR3 Inhibitors as Therapeutic for Pain
Invention: The technology identifies protease activated receptor-3 (PAR3) and PAR3 inhibitors as a novel target for the treatment of pain.
Background: Pain is one of the most common reasons in which individuals seek medical attention. Globally, pain affects at least 1.5 billion people, with the incidence rate increasing complementary to age. Current treatments for chronic pain can be harmful to patients in that there is a history of abuse accompanied by intolerable side effects. This technology has the potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain.
- Pain therapeutics
- Mitigation of periodontitis
- Potential for application in cancer
- Potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain